Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Boehringer Japan’s Ethical Drug Sales Tick Up 2% in 2015
April 26, 2016
- Novartis Seeks Add’l Indications for Ilaris in Japan
April 26, 2016
- Novartis Looks to Harness Big Data for Indication Expansions: Global Medical Chief
April 26, 2016
- MSD, Sanofi to End RotaTeq, Heptavax Copromotion in Japan
April 25, 2016
- Janssen Files Simponi for Ulcerative Colitis in Japan
April 25, 2016
- Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
- Novo Nordisk’s Japan Sales Log Record 89 Billion Yen on Tresiba, Victoza
April 22, 2016
- Around 140 Clinical Trials of Nucleic Acid Drugs Underway Worldwide, with Cancer, Neuropathy, and Myopathy as Main Targets
April 22, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- Ajinomoto Pulls Out from JV with Yoshindo as EA Pharma Launched
April 21, 2016
- MSD’s Hep C Drugs Get Priority Review Status in Japan
April 20, 2016
- Biogen Files MS Treatment Dimethyl Fumarate in Japan
April 20, 2016
- FunPep, Morishita Jintan Sign MOU to Commercialize Products Containing Antibacterial Peptide
April 19, 2016
- AbbVie Starts Japan PIIb/III Study of Selective JAK1 Inhibitor in RA Patients
April 19, 2016
- Heptares, Kymab Tie Up for Joint Research on Cancer Immunotherapy
April 19, 2016
- Wholesalers Say Drug Distributions in Quake-Hit Kumamoto More or Less Stable
April 19, 2016
- Sanwa Kagaku’s Kumamoto Factory Shuts Down after Quake
April 18, 2016
- Kaketsuken Halts Operations on April 18-20 after Quake
April 18, 2016
- Announcement: 9th Annual eyeforpharma Japan 2016 - Westin Tokyo, July 13-14
April 15, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…